CareDx, Inc (CDNA)

Market Cap	1.06B
Revenue (ttm)	333.79M
Net Income (ttm)	52.55M
Shares Out	55.43M
EPS (ttm)	0.93
PE Ratio	20.49
Forward PE	31.50
Dividend	n/a
Ex-Dividend Date	n/a

Volume	519,591
Open	19.50
Previous Close	19.61
Day's Range	18.84 - 19.60
52-Week Range	7.42 - 34.84
Beta	1.95
Analysts	Buy
Price Target	29.43 (+54.41%)
Earnings Date	May 8, 2025

About CDNA

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to typ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 17, 2014
• Employees: 650
• Stock Exchange: NASDAQ
• Ticker Symbol: CDNA
• Website: https://caredx.com

Analyst Forecast

According to 8 analysts, the average rating for CDNA stock is "Buy." The 12-month stock price forecast is $29.43, which is an increase of 54.41% from the latest price.

Price Target

$29.43

(54.41% upside)

Analyst Consensus: Buy